REDWOOD CITY, CA, USA I May 14, 2024 I Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for ...

MISSOULA, MT, USA I May 15, 2024 I Inimmune, a leading clinical stage biotech company focused on the development of novel vaccine adjuvants, immunotherapies ...

Only about half of folks with Type 2 diabetes have their blood sugar under control and regularly achieve an A1C of 7% or less. That puts them at increased risk ...

Viking Therapeutics (VKTX) stock falls after Roche (RHHBY) posted promising Phase 1 results for its experimental obesity ...

Other findings from the latest Kaiser Family Foundation Health Tracking Poll shed light on public awareness, use, and ...

GIP receptor agonist, which it gained in the Carmot acquisition, showed 18.8% weight loss in a Phase Ib trial.

The results, which showed Lilly’s drug was as effective at controlling blood sugar as standard injections, come as Novo Nordisk seeks approval for a competing once-weekly insulin.

A recent clinical trial of Wegovy showed that 17 percent of patients on the drug left the trial because of side effects.

A KFF poll also suggests half of the respondents who had tried these weight loss meds no longer took them, with many ...

Gathered from Dandelion’s 3 health system partners, the GLP-1 Data Library reflects the longitudinal patient records for 10 ...

Researchers assessed whether glucagon-like peptide-1 receptor agonists promote weight loss and changes in BMI and HBA1c in patients with HIV infection.